Understand how TissueCypher® predicts future development of HGD/EAC in patients with BE. Impacts patient-care decisions as demonstrated by case studies.

Dr. Barry White shares cases of challenging melanocytic lesions in which gene expression profiling (GEP) was utilized to inform the diagnosis when histopathological findings were insufficient to render a definitive diagnosis

Dr. Drazen Jukic presents challenging cases in which gene expression profiling (GEP) was utilized to inform the diagnosis of ambiguous melanocytic lesions.

Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.

Clinical Gastroenterolgy and Hepatology 2022

We have become excellent at treating Barrett’s esophagus (BE) related neoplasia. But to reduce the instance of esophageal adenocarcinoma (EAC) we need to increase the population under surveillance and leverage risk stratification tools to personalize the management of non-dysplastic BE.